REFERENCES
3. Dasari S, Tchounwou PB. Cisplatin in cancer therapy: molecular mechanisms of action. Eur J Pharmacol 2014;740:364-78.
4. Keating GM, Santoro A. Sorafenib: a review of its use in advanced hepatocellular carcinoma. Drugs 2009;69:223-40.
5. Hagner N, Joerger M. Cancer chemotherapy: targeting folic acid synthesis. Cancer Manag Res 2010;2:293-301.
6. Caitriona H, Sandra Van S, Daniel BL, Patrick GJ. Cancer drug resistance: an evolving paradigm. Nat Rev Cancer 2013;13:714.
7. Gloss BS, Dinger ME. Realizing the significance of noncoding functionality in clinical genomics. Exp Mol Med 2018;50:97.
8. Yamada A, Yu P, Lin W, Okugawa Y, Boland CR, et al. A RNA-sequencing approach for the identification of novel long non-coding RNA biomarkers in colorectal cancer. Sci Rep 2018;8:575.
10. Quinn JJ, Chang HY. Unique features of long non-coding RNA biogenesis and function. Nat Rev Genet 2016;17:47-62.
11. Zhang Y, Yang L, Chen LL. Life without A tail: new formats of long noncoding RNAs. Int J Biochem Cell Biol 2014;54:338-49.
12. Ransohoff JD, Wei Y, Khavari PA. The functions and unique features of long intergenic non-coding RNA. Nat Rev Mol Cell Biol 2018;19:143-57.
13. Li Y, Ye Y, Feng B, Qi Y. Long noncoding RNA lncARSR promotes doxorubicin resistance in hepatocellular carcinoma via modulating PTEN-PI3K/Akt pathway. J Cell Biochem 2017;118:4498-507.
14. Shi SJ, Wang LJ, Yu B, Li YH, Jin Y, et al. LncRNA-ATB promotes trastuzumab resistance and invasion-metastasis cascade in breast cancer. Oncotarget 2015;6:11652-63.
15. Godinho MF, Wulfkuhle JD, Look MP, Sieuwerts AM, Sleijfer S, et al. BCAR4 induces antioestrogen resistance but sensitises breast cancer to lapatinib. Br J Cancer 2012;107:947-55.
16. Li Y, Lv S, Ning H, Li K, Zhou X, et al. Down-regulation of CASC2 contributes to cisplatin resistance in gastric cancer by sponging miR-19a. Biomed Pharmacother 2018;108:1775-82.
17. Zhang Y, Li Q, Yu S, Zhu C, Zhang Z, et al. Long non-coding RNA FAM84B-AS promotes resistance of gastric cancer to platinum drugs through inhibition of FAM84B expression. Biochem Biophys Res Commun 2019;509:753-62.
18. Zhang CL, Zhu KP, Ma XL. Antisense lncRNA FOXC2-AS1 promotes doxorubicin resistance in osteosarcoma by increasing the expression of FOXC2. Cancer Lett 2017;396:66-75.
19. An Q, Zhou L, Xu N. Long noncoding RNA FOXD2-AS1 accelerates the gemcitabine-resistance of bladder cancer by sponging miR-143. Biomed Pharmacother 2018;103:415-20.
20. Li W, Zhai L, Wang H, Liu C, Zhang J, et al. Downregulation of LncRNA GAS5 causes trastuzumab resistance in breast cancer. Oncotarget 2016;7:27778-86.
21. Cai Q, Wang S, Jin L, Weng M, Zhou D, et al. Long non-coding RNA GBCDRlnc1 induces chemoresistance of gallbladder cancer cells by activating autophagy. Mol Cancer 2019;18:82.
22. Han J, Han B, Wu X, Hao J, Dong X, et al. Knockdown of lncRNA H19 restores chemo-sensitivity in paclitaxel-resistant triple-negative breast cancer through triggering apoptosis and regulating Akt signaling pathway. Toxicol Appl Pharmacol 2018;359:55-61.
23. Jia L, Tian Y, Chen Y, Zhang G. The silencing of LncRNA-H19 decreases chemoresistance of human glioma cells to temozolomide by suppressing epithelial-mesenchymal transition via the Wnt/beta-Catenin pathway. Onco Targets Ther 2018;11:313-21.
24. Xiao J, Lv Y, Jin F, Liu Y, Ma Y, et al. LncRNA HANR promotes tumorigenesis and increase of chemoresistance in hepatocellular carcinoma. Cell Physiol Biochem 2017;43:1926-38.
25. Chen X, Liu M, Meng F, Sun B, Jin X, et al. The long noncoding RNA HIF1A-AS2 facilitates cisplatin resistance in bladder cancer. J Cell Biochem 2019;120:243-52.
26. Xue X, Yang YA, Zhang A, Fong KW, Kim J, et al. LncRNA HOTAIR enhances ER signaling and confers tamoxifen resistance in breast cancer. Oncogene 2016;35:2746-55.
27. Xiao Z, Qu Z, Chen Z, Fang Z, Zhou K, et al. LncRNA HOTAIR is a prognostic biomarker for the proliferation and chemoresistance of colorectal cancer via MiR-203a-3p-mediated Wnt/ss-catenin signaling pathway. Cell Physiol Biochem 2018;46:1275-85.
28. Yang Y, Jiang C, Yang Y, Guo L, Huang J, et al. Silencing of LncRNA-HOTAIR decreases drug resistance of non-small cell lung cancer cells by inactivating autophagy via suppressing the phosphorylation of ULK1. Biochem Biophys Res Commun 2018;497:1003-10.
29. Zhou H, Ma Y, Zhong D, Yang L. Knockdown of lncRNA HOXD-AS1 suppresses proliferation, migration and invasion and enhances cisplatin sensitivity of glioma cells by sponging miR-204. Biomed Pharmacother 2019;112:108633.
30. Gu P, Chen X, Xie R, Han J, Xie W, et al. lncRNA HOXD-AS1 regulates proliferation and chemo-resistance of castration-resistant prostate cancer via recruiting WDR5. Mol Ther 2017;25:1959-73.
31. Chen X, Xie R, Gu P, Huang M, Han J, et al. Long Noncoding RNA LBCS inhibits self-renewal and chemoresistance of bladder cancer stem cells through epigenetic silencing of SOX2. Clin Cancer Res 2019;25:1389-403.
32. Zhuang J, Shen L, Yang L, Huang X, Lu Q, et al. TGFbeta1 promotes gemcitabine resistance through regulating the LncRNA-LET/NF90/miR-145 signaling axis in bladder cancer. Theranostics 2017;7:3053-67.
33. Ma G, Zhu J, Liu F, Yang Y. Long noncoding RNA LINC00460 promotes the gefitinib resistance of nonsmall cell lung cancer through epidermal growth factor receptor by sponging miR-769-5p. DNA Cell Biol 2019;38:176-83.
34. He J, Sun M, Geng H, Tian S. Long non-coding RNA Linc00518 promotes paclitaxel resistance of the human prostate cancer by sequestering miR-216b-5p. Biol Cell 2019;111:39-50.
35. Han Z, Shi L. Long non-coding RNA LUCAT1 modulates methotrexate resistance in osteosarcoma via miR-200c/ABCB1 axis. Biochem Biophys Res Commun 2018;495:947-53.
36. He W, Liang B, Wang C, Li S, Zhao Y, et al. MSC-regulated lncRNA MACC1-AS1 promotes stemness and chemoresistance through fatty acid oxidation in gastric cancer. Oncogene 2019;38:4637-54.
37. Li P, Zhang X, Wang H, Wang L, Liu T, et al. MALAT1 is associated with poor response to oxaliplatin-based chemotherapy in colorectal cancer patients and promotes chemoresistance through EZH2. Mol Cancer Ther 2017;16:739-51.
38. Li P, Xing W, Xu J, Yuan D, Liang G, et al. microRNA-301b-3p downregulation underlies a novel inhibitory role of long non-coding RNA MBNL1-AS1 in non-small cell lung cancer. Stem Cell Res Ther 2019;10:144.
39. Liu J, Wan L, Lu K, Sun M, Pan X, et al. The long noncoding RNA MEG3 contributes to cisplatin resistance of human lung adenocarcinoma. PLoS One 2015;10:e0114586.
40. Chen S, Xia X. Long noncoding RNA NEAT1 suppresses sorafenib sensitivity of hepatocellular carcinoma cells via regulating miR-335-c-Met. J Cell Physiol 2019; doi: 10.1002/jcp.27567.
41. Hu Y, Yang Q, Wang L, Wang S, Sun F, et al. Knockdown of the oncogene lncRNA NEAT1 restores the availability of miR-34c and improves the sensitivity to cisplatin in osteosarcoma. Biosci Rep 2018;38.
42. Tian X, Zhang G, Zhao H, Li Y, Zhu C. Long non-coding RNA NEAT1 contributes to docetaxel resistance of prostate cancer through inducing RET expression by sponging miR-34a. RSC Advances 2017;7:42986-96.
43. Song L, Zhou Z, Gan Y, Li P, Xu Y, et al. Long noncoding RNA OIP5-AS1 causes cisplatin resistance in osteosarcoma through inducing the LPAATbeta/PI3K/AKT/mTOR signaling pathway by sponging the miR-340-5p. J Cell Biochem 2019;120:9656-66.
44. Fan H, Zhu JH, Yao XQ. Knockdown of long noncoding RNA PVT1 reverses multidrug resistance in colorectal cancer cells. Mol Med Rep 2018;17:8309-15.
45. Ping G, Xiong W, Zhang L, Li Y, Zhang Y, et al. Silencing long noncoding RNA PVT1 inhibits tumorigenesis and cisplatin resistance of colorectal cancer. Am J Transl Res 2018;10:138-49.
46. Du P, Hu C, Qin Y, Zhao J, Patel R, et al. LncRNA PVT1 mediates antiapoptosis and 5-fluorouracil resistance via increasing Bcl2 expression in gastric cancer. J Oncol 2019;2019:10.
47. Zhang Z, Yin J, Lu C, Wei Y, Zeng A, et al. Exosomal transfer of long non-coding RNA SBF2-AS1 enhances chemoresistance to temozolomide in glioblastoma. J Exp Clin Cancer Res 2019;38:166.
48. Li W, Dong X, He C, Tan G, Li Z, et al. LncRNA SNHG1 contributes to sorafenib resistance by activating the Akt pathway and is positively regulated by miR-21 in hepatocellular carcinoma cells. J Exp Clin Cancer Res 2019;38:183.
49. Wang P, Chen D, Ma H, Li Y. LncRNA SNHG12 contributes to multidrug resistance through activating the MAPK/Slug pathway by sponging miR-181a in non-small cell lung cancer. Oncotarget 2017;8:84086-101.
50. Wang L, Shang X, Feng Q. LncRNA TATDN1 contributes to the cisplatin resistance of non-small cell lung cancer through TATDN1/miR-451/TRIM66 axis. Cancer Biol Ther 2019;20:261-71.
51. Song H, Xu Y, Shi L, Xu T, Fan R, et al. LncRNA THOR increases the stemness of gastric cancer cells via enhancing SOX9 mRNA stability. Biomed Pharmacother 2018;108:338-46.
52. Mazor G, Levin L, Picard D, Ahmadov U, Caren H, et al. The lncRNA TP73-AS1 is linked to aggressiveness in glioblastoma and promotes temozolomide resistance in glioblastoma cancer stem cells. Cell Death Dis 2019;10:246.
53. Li C, Gao Y, Li Y, Ding D. TUG1 mediates methotrexate resistance in colorectal cancer via miR-186/CPEB2 axis. Biochem Biophys Res Commun 2017;491:552-7.
54. Yang LT, Du Y, Yu PF, Fan J, Wang XB, et al. Long non-coding RNA TUG1 regulates the development of multidrug resistance in hepatocellular carcinoma via P-gp and MDR1. Int J Clin Exp Med 2016;9:21388-96.
55. Fan Y, Shen B, Tan M, Mu X, Qin Y, et al. Long non-coding RNA UCA1 increases chemoresistance of bladder cancer cells by regulating Wnt signaling. Febs J 2014;281:1750-8.
56. Wu C, Luo J. Long non-coding RNA (lncRNA) urothelial carcinoma-associated 1 (UCA1) enhances tamoxifen resistance in breast cancer cells via inhibiting mTOR signaling pathway. Med Sci Monit 2016;22:3860-7.
57. Bian Z, Jin L, Zhang J, Yin Y, Quan C, et al. LncRNA-UCA1 enhances cell proliferation and 5-fluorouracil resistance in colorectal cancer by inhibiting miR-204-5p. Sci Rep 2016;6:23892.
58. Cheng N, Cai W, Ren S, Li X, Wang Q, et al. Long non-coding RNA UCA1 induces non-T790M acquired resistance to EGFR-TKIs by activating the AKT/mTOR pathway in EGFR-mutant non-small cell lung cancer. Oncotarget 2015;6:23582-93.
59. Wang X, Yang B, Ma B. The UCA1/miR-204/Sirt1 axis modulates docetaxel sensitivity of prostate cancer cells. Cancer Chemother Pharmacol 2016;78:1025-31.
60. Zhu J, Zhang R, Yang D, Li J, Yan X, et al. Knockdown of long non-coding RNA XIST inhibited doxorubicin resistance in colorectal cancer by upregulation of miR-124 and downregulation of SGK1. Cell Physiol Biochem 2018;51:113-28.
61. Xu W, He L, Li Y, Tan Y, Zhang F, et al. Silencing of lncRNA ZFAS1 inhibits malignancies by blocking Wnt/beta-catenin signaling in gastric cancer cells. Biosci Biotechnol Biochem 2018;82:456-65.
62. Schirrmacher V. From chemotherapy to biological therapy: a review of novel concepts to reduce the side effects of systemic cancer treatment (Review). Int J Oncol 2019;54:407-19.
63. Allen KE, Weiss GJ. Resistance may not be futile: microRNA biomarkers for chemoresistance and potential therapeutics. Mol Cancer Ther 2010;9:3126-36.
65. Lee CY. Strategies of temozolomide in future glioblastoma treatment. Onco Targets Ther 2017;10:265-70.
66. Chen X, Wu Y, Dong H, Zhang CY, Zhang Y. Platinum-based agents for individualized cancer treatment. Curr Mol Med 2013;13:1603-12.
67. Matsuda A, Yamaoka K, Tango T. Quality of life in advanced non-small cell lung cancer patients receiving palliative chemotherapy: a meta-analysis of randomized controlled trials. Exp Ther Med 2012;3:134-40.
68. Morgensztern D, Ng SH, Gao F, Govindan R. Trends in stage distribution for patients with non-small cell lung cancer: a national cancer database survey. J Thorac Oncol 2010;5:29-33.
69. Kamat AM, Hahn NM, Efstathiou JA, Lerner SP, Malmstrom PU, et al. Bladder cancer. Lancet 2016;388:2796-810.
70. Kurtova AV, Xiao J, Mo Q, Pazhanisamy S, Krasnow R, et al. Blocking PGE2-induced tumour repopulation abrogates bladder cancer chemoresistance. Nature 2015;517:209-13.
71. Luo J, Chen J, Li H, Yang Y, Yun H, et al. LncRNA UCA1 promotes the invasion and EMT of bladder cancer cells by regulating the miR-143/HMGB1 pathway. Oncol Lett 2017;14:5556-62.
72. Wang H, Guan Z, He K, Qian J, Cao J, et al. LncRNA UCA1 in anti-cancer drug resistance. Oncotarget 2017;8:64638-50.
73. Sastre J, Garcia-Saenz JA, Diaz-Rubio E. Chemotherapy for gastric cancer. World J Gastroenterol 2006;12:204-13.
74. Oba K, Paoletti X, Bang YJ, Bleiberg H, Burzykowski T, et al. Role of chemotherapy for advanced/recurrent gastric cancer: an individual-patient-data meta-analysis. Eur J Cancer 2013;49:1565-77.
75. Wong N, Gu Y, Kapoor A, Lin X, Ojo D, et al. Upregulation of FAM84B during prostate cancer progression. Oncotarget 2017;8:19218-35.
76. Alcindor T, Beauger N. Oxaliplatin: a review in the era of molecularly targeted therapy. Curr Oncol 2011;18:18-25.
77. Houthuijzen JM, Daenen LG, Roodhart JM, Voest EE. The role of mesenchymal stem cells in anti-cancer drug resistance and tumour progression. Br J Cancer 2012;106:1901-6.
78. Roodhart JM, Daenen LG, Stigter EC, Prins HJ, Gerrits J, et al. Mesenchymal stem cells induce resistance to chemotherapy through the release of platinum-induced fatty acids. Cancer Cell 2011;20:370-83.
79. Wang T, Fahrmann JF, Lee H, Li YJ, Tripathi SC, et al. JAK/STAT3-regulated fatty acid beta-oxidation is critical for breast cancer stem cell self-renewal and chemoresistance. Cell Metab 2018;27:1357.
80. Rowinsky EK. The development and clinical utility of the taxane class of antimicrotubule chemotherapy agents. Annu Rev Med 1997;48:353-74.
81. Yao H, He G, Yan S, Chen C, Song L, et al. Triple-negative breast cancer: is there a treatment on the horizon? Oncotarget 2017;8:1913-24.
82. Ivery MT, Le T. Modeling the interaction of paclitaxel with beta-tubulin. Oncol Res 2003;14:1-19.
83. Raveh E, Matouk IJ, Gilon M, Hochberg A. The H19 Long non-coding RNA in cancer initiation, progression and metastasis - a proposed unifying theory. Mol Cancer 2015;14:184.
84. Attard G, Parker C, Eeles RA, Schroder F, Tomlins SA, et al. Prostate cancer. Lancet 2016;387:70-82.
85. Chakravarty D, Sboner A, Nair SS, Giannopoulou E, Li R, et al. The oestrogen receptor alpha-regulated lncRNA NEAT1 is a critical modulator of prostate cancer. Nat Commun 2014;5:5383.
86. Naganuma T, Hirose T. Paraspeckle formation during the biogenesis of long non-coding RNAs. RNA Biol 2013;10:456-61.
87. Thorn CF, Oshiro C, Marsh S, Hernandez-Boussard T, McLeod H, et al. Doxorubicin pathways: pharmacodynamics and adverse effects. Pharmacogenet Genomics 2011;21:440-6.
88. Misra S, Chaturvedi A, Misra NC, Sharma ID. Carcinoma of the gallbladder. Lancet Oncol 2003;4:167-76.
89. Kresl JJ, Schild SE, Henning GT, Gunderson LL, Donohue J, et al. Adjuvant external beam radiation therapy with concurrent chemotherapy in the management of gallbladder carcinoma. Int J Radiat Oncol Biol Phys 2002;52:167-75.
90. Pei G, Luo M, Ni X, Wu J, Wang S, et al. Autophagy facilitates metadherin-induced chemotherapy resistance through the AMPK/ATG5 pathway in gastric cancer. Cell Physiol Biochem 2018;46:847-59.
91. Arencibia JM, Pastor-Flores D, Bauer AF, Schulze JO, Biondi RM. AGC protein kinases: from structural mechanism of regulation to allosteric drug development for the treatment of human diseases. Biochim Biophys Acta 2013;1834:1302-21.
92. Tanaka S, Arii S. Molecular targeted therapy for hepatocellular carcinoma in the current and potential next strategies. J Gastroenterol 2011;46:289-96.
93. Sano H, Leboeuf JP, Novitskiy SV, Seo S, Zaja-Milatovic S, et al. The Foxc2 transcription factor regulates tumor angiogenesis. Biochem Biophys Res Commun 2010;392:201-6.
94. Plunkett W, Huang P, Xu YZ, Heinemann V, Grunewald R, et al. Gemcitabine: metabolism, mechanisms of action, and self-potentiation. Semin Oncol 1995;22:3-10.
95. Liu X, Yao D, Liu C, Cao Y, Yang Q, et al. Overexpression of ABCC3 promotes cell proliferation, drug resistance, and aerobic glycolysis and is associated with poor prognosis in urinary bladder cancer patients. Tumour Biol 2016;37:8367-74.
96. Sara JD, Kaur J, Khodadadi R, Rehman M, Lobo R, et al. 5-fluorouracil and cardiotoxicity: a review. Ther Adv Med Oncol 2018; doi: 10.1177/1758835919871363.
97. Miura K, Kinouchi M, Ishida K, Fujibuchi W, Naitoh T, et al. 5-fu metabolism in cancer and orally-administrable 5-fu drugs. Cancers 2010;2:1717-30.
98. Carter SK, Comis RL. Gastric cancer: current status of treatment. J Natl Cancer Inst 1977;58:567-78.
99. Wilhelm S, Carter C, Lynch M, Lowinger T, Dumas J, et al. Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nat Rev Drug Discov 2006;5:835-44.
100. Guo S, Chen W, Luo Y, Ren F, Zhong T, et al. Clinical implication of long non-coding RNA NEAT1 expression in hepatocellular carcinoma patients. Int J Clin Exp Pathol 2015;8:5395-402.
102. Guo F, Cao Z, Guo H, Li S. The action mechanism of lncRNA-HOTAIR on the drug resistance of non-small cell lung cancer by regulating Wnt signaling pathway. Exp Ther Med 2018;15:4885-9.
104. Arteaga CL. Trastuzumab, an appropriate first-line single-agent therapy for HER2-overexpressing metastatic breast cancer. Breast Cancer Res 2003;5:96-100.
105. Gajria D, Chandarlapaty S. HER2-amplified breast cancer: mechanisms of trastuzumab resistance and novel targeted therapies. Expert Rev Anticancer Ther 2011;11:263-75.
106. Montemurro F, Donadio M, Clavarezza M, Redana S, Jacomuzzi ME, et al. Outcome of patients with HER2-positive advanced breast cancer progressing during trastuzumab-based therapy. Oncologist 2006;11:318-24.
107. Niedersuss-Beke D, Puntus T, Kunit T, Grunberger B, Lamche M, et al. Neoadjuvant chemotherapy with gemcitabine plus cisplatin in patients with locally advanced bladder cancer. Oncology 2017;93:36-42.
108. Nishio M, Kim DW, Wu YL, Nakagawa K, Solomon BJ, et al. Crizotinib versus chemotherapy in Asian patients with ALK-positive advanced non-small cell lung cancer. Cancer Res Treat 2018;50:691-700.
109. Camidge DR, Otterson GA, Clark JW, Ou SHI, Weiss J, et al. Crizotinib in patients (pts) with MET-amplified non-small cell lung cancer (NSCLC): updated safety and efficacy findings from a phase 1 trial. J Clin Oncol 2018;36:9062.
110. Rau KM, Kang HY, Cha TL, Miller SA, Hung MC. The mechanisms and managements of hormone-therapy resistance in breast and prostate cancers. Endocr Relat Cancer 2005;12:511-32.
111. Fan C, Oh DS, Wessels L, Weigelt B, Nuyten DS, et al. Concordance among gene-expression-based predictors for breast cancer. N Engl J Med 2006;355:560-9.
113. Tremont A, Lu J, Cole JT. Endocrine therapy for early breast cancer: updated review. Ochsner J 2017;17:405-11.
114. Sporn MB LS. Agents for chemoprevention and their mechanism of action. Holland-Frei Cancer Medicine: BC Decker; 2003.
115. Godinho MF, Sieuwerts AM, Look MP, Meijer D, Foekens JA, et al. Relevance of BCAR4 in tamoxifen resistance and tumour aggressiveness of human breast cancer. Br J Cancer 2010;103:1284-91.
116. Liu H, Wang G, Yang L, Qu J, Yang Z, et al. Knockdown of long non-coding RNA UCA1 increases the tamoxifen sensitivity of breast cancer cells through inhibition of Wnt/beta-catenin pathway. PLoS One 2016;11:e0168406.
117. Feng Y, Hu X, Zhang Y, Zhang D, Li C, et al. Methods for the study of long noncoding RNA in cancer cell signaling. Methods Mol Biol 2014;1165:115-43.
118. Arun G, Diermeier S, Akerman M, Chang KC, Wilkinson JE, et al. Differentiation of mammary tumors and reduction in metastasis upon Malat1 lncRNA loss. Genes Dev 2016;30:34-51.
119. Gutschner T, Hammerle M, Eissmann M, Hsu J, Kim Y, et al. The noncoding RNA MALAT1 is a critical regulator of the metastasis phenotype of lung cancer cells. Cancer Res 2013;73:1180-9.
120. Yin DD, Liu ZJ, Zhang E, Kong R, Zhang ZH, et al. Decreased expression of long noncoding RNA MEG3 affects cell proliferation and predicts a poor prognosis in patients with colorectal cancer. Tumour Biol 2015;36:4851-9.
121. Marin-Bejar O, Marchese FP, Athie A, Sanchez Y, Gonzalez J, et al. Pint lincRNA connects the p53 pathway with epigenetic silencing by the Polycomb repressive complex 2. Genome Biol 2013;14:R104.
